Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Anti-Glomerular Basement Membrane Disease | 22 | 2023 | 23 | 7.020 |
Why?
|
Collagen Type IV | 33 | 2021 | 48 | 5.060 |
Why?
|
Autoantibodies | 20 | 2023 | 103 | 4.250 |
Why?
|
Autoantigens | 20 | 2021 | 81 | 3.200 |
Why?
|
Glomerulonephritis, Membranous | 5 | 2022 | 9 | 2.750 |
Why?
|
Nephritis, Hereditary | 14 | 2014 | 14 | 2.520 |
Why?
|
Immunoglobulin G | 11 | 2023 | 237 | 2.480 |
Why?
|
Glomerular Basement Membrane | 6 | 2019 | 9 | 1.960 |
Why?
|
Laminin | 8 | 2023 | 61 | 1.880 |
Why?
|
Glomerulonephritis | 6 | 2016 | 13 | 1.480 |
Why?
|
Kidney | 10 | 2021 | 337 | 1.180 |
Why?
|
Isoantibodies | 6 | 2013 | 7 | 1.160 |
Why?
|
Epitopes | 9 | 2021 | 148 | 1.070 |
Why?
|
Kidney Glomerulus | 10 | 2022 | 84 | 1.020 |
Why?
|
Kidney Transplantation | 5 | 2013 | 86 | 0.970 |
Why?
|
Disease Models, Animal | 9 | 2013 | 1371 | 0.830 |
Why?
|
Basement Membrane | 10 | 2022 | 28 | 0.800 |
Why?
|
Hemoptysis | 1 | 2021 | 3 | 0.790 |
Why?
|
Complement Activation | 2 | 2022 | 13 | 0.780 |
Why?
|
Mice, Transgenic | 9 | 2019 | 617 | 0.710 |
Why?
|
Antigen-Antibody Complex | 2 | 2022 | 19 | 0.680 |
Why?
|
Animals | 38 | 2023 | 15081 | 0.660 |
Why?
|
Epitope Mapping | 5 | 2013 | 31 | 0.650 |
Why?
|
Lupus Nephritis | 2 | 2016 | 23 | 0.640 |
Why?
|
Mice | 23 | 2021 | 5913 | 0.610 |
Why?
|
Heparitin Sulfate | 2 | 2016 | 23 | 0.600 |
Why?
|
Humans | 44 | 2023 | 37093 | 0.590 |
Why?
|
Immunoglobulin A | 2 | 2008 | 58 | 0.570 |
Why?
|
Proteins | 4 | 2005 | 369 | 0.560 |
Why?
|
Antibody Specificity | 3 | 2013 | 79 | 0.540 |
Why?
|
Collagen | 6 | 2005 | 172 | 0.540 |
Why?
|
Kidney Failure, Chronic | 4 | 2021 | 233 | 0.520 |
Why?
|
Receptors, Fc | 1 | 2013 | 7 | 0.470 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2013 | 21 | 0.470 |
Why?
|
CD4-Positive T-Lymphocytes | 2 | 2012 | 259 | 0.470 |
Why?
|
Plasminogen | 3 | 2004 | 10 | 0.440 |
Why?
|
Autoimmune Diseases | 3 | 2015 | 57 | 0.440 |
Why?
|
Gene Expression Regulation | 2 | 2016 | 1015 | 0.430 |
Why?
|
Immune Tolerance | 1 | 2013 | 65 | 0.430 |
Why?
|
Nephrotic Syndrome | 1 | 2012 | 10 | 0.410 |
Why?
|
Protein Structure, Tertiary | 9 | 2013 | 408 | 0.410 |
Why?
|
Antigens | 2 | 2008 | 56 | 0.400 |
Why?
|
Mice, Knockout | 11 | 2016 | 933 | 0.350 |
Why?
|
Protein Structure, Quaternary | 5 | 2013 | 64 | 0.330 |
Why?
|
Antibodies, Monoclonal | 4 | 2008 | 290 | 0.330 |
Why?
|
Glomerulonephritis, Membranoproliferative | 2 | 2009 | 3 | 0.320 |
Why?
|
Nephritis | 2 | 2010 | 6 | 0.320 |
Why?
|
Epitopes, B-Lymphocyte | 2 | 2008 | 12 | 0.310 |
Why?
|
Protein Binding | 8 | 2008 | 972 | 0.310 |
Why?
|
Mice, Inbred C57BL | 7 | 2016 | 1609 | 0.300 |
Why?
|
Isoantigens | 1 | 2007 | 5 | 0.300 |
Why?
|
Complement Factor H | 2 | 2016 | 5 | 0.280 |
Why?
|
Antibodies | 2 | 2010 | 141 | 0.280 |
Why?
|
Immunity, Innate | 1 | 2007 | 149 | 0.280 |
Why?
|
Male | 14 | 2021 | 20025 | 0.260 |
Why?
|
Hemostasis | 1 | 2005 | 6 | 0.260 |
Why?
|
Antigen-Antibody Reactions | 1 | 2005 | 20 | 0.260 |
Why?
|
Immunoglobulin Allotypes | 1 | 2005 | 5 | 0.260 |
Why?
|
Protein Conformation | 7 | 2010 | 389 | 0.260 |
Why?
|
Collagen Type I | 1 | 2005 | 30 | 0.250 |
Why?
|
Blood Proteins | 3 | 2005 | 66 | 0.240 |
Why?
|
Disease Progression | 3 | 2021 | 601 | 0.240 |
Why?
|
Complement C3 | 2 | 2016 | 16 | 0.240 |
Why?
|
Lung | 2 | 2021 | 446 | 0.240 |
Why?
|
Recombinant Fusion Proteins | 5 | 2012 | 295 | 0.240 |
Why?
|
Podocytes | 3 | 2009 | 35 | 0.230 |
Why?
|
Glycoproteins | 1 | 2004 | 106 | 0.230 |
Why?
|
Female | 11 | 2023 | 20969 | 0.230 |
Why?
|
Glycosaminoglycans | 2 | 2004 | 22 | 0.220 |
Why?
|
Thrombospondins | 1 | 2022 | 3 | 0.220 |
Why?
|
Proteinuria | 2 | 2021 | 50 | 0.210 |
Why?
|
Mice, Inbred DBA | 2 | 2013 | 71 | 0.210 |
Why?
|
Complement System Proteins | 1 | 2022 | 21 | 0.210 |
Why?
|
Albuminuria | 2 | 2013 | 76 | 0.210 |
Why?
|
Tissue Plasminogen Activator | 2 | 2004 | 22 | 0.210 |
Why?
|
Receptors, Phospholipase A2 | 1 | 2021 | 1 | 0.200 |
Why?
|
Protein Isoforms | 5 | 2010 | 130 | 0.200 |
Why?
|
Fumarates | 1 | 2021 | 11 | 0.200 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 5 | 2010 | 448 | 0.200 |
Why?
|
Saimiri | 1 | 2021 | 6 | 0.200 |
Why?
|
Membrane Glycoproteins | 2 | 2016 | 211 | 0.200 |
Why?
|
Muscle, Smooth | 1 | 2001 | 58 | 0.190 |
Why?
|
Creatinine | 1 | 2021 | 103 | 0.190 |
Why?
|
Transplantation, Homologous | 2 | 2013 | 36 | 0.190 |
Why?
|
Cattle | 4 | 2013 | 477 | 0.180 |
Why?
|
Models, Molecular | 5 | 2008 | 808 | 0.180 |
Why?
|
Animals, Newborn | 2 | 2019 | 343 | 0.180 |
Why?
|
Hydrogen-Ion Concentration | 4 | 2005 | 364 | 0.170 |
Why?
|
Immunity, Humoral | 1 | 2019 | 24 | 0.170 |
Why?
|
Prognosis | 1 | 2021 | 739 | 0.160 |
Why?
|
Plasma | 1 | 1998 | 31 | 0.160 |
Why?
|
Case-Control Studies | 1 | 2021 | 1130 | 0.150 |
Why?
|
Amino Acid Sequence | 6 | 2013 | 1180 | 0.150 |
Why?
|
Molecular Sequence Data | 6 | 2013 | 1568 | 0.150 |
Why?
|
Aged | 4 | 2021 | 6741 | 0.140 |
Why?
|
Complement C3b | 1 | 2016 | 2 | 0.140 |
Why?
|
Agrin | 1 | 2016 | 5 | 0.140 |
Why?
|
Retrospective Studies | 2 | 2021 | 2026 | 0.140 |
Why?
|
Receptors, Complement | 1 | 2016 | 2 | 0.140 |
Why?
|
Complement Pathway, Alternative | 1 | 2016 | 2 | 0.140 |
Why?
|
Static Electricity | 1 | 2016 | 78 | 0.140 |
Why?
|
Sequence Homology, Amino Acid | 3 | 2013 | 269 | 0.140 |
Why?
|
Dimerization | 3 | 2008 | 112 | 0.140 |
Why?
|
Blister | 1 | 2015 | 2 | 0.130 |
Why?
|
Peroxidase | 2 | 2013 | 49 | 0.130 |
Why?
|
Gene Expression Regulation, Developmental | 2 | 2008 | 286 | 0.130 |
Why?
|
Cell Line | 4 | 2005 | 1354 | 0.130 |
Why?
|
Pregnancy | 2 | 2019 | 1549 | 0.130 |
Why?
|
Oligoribonucleotides, Antisense | 1 | 2014 | 3 | 0.130 |
Why?
|
Rabbits | 4 | 2008 | 283 | 0.120 |
Why?
|
Postoperative Complications | 2 | 2013 | 210 | 0.120 |
Why?
|
Skin | 1 | 2015 | 174 | 0.120 |
Why?
|
Smoking | 1 | 2021 | 940 | 0.120 |
Why?
|
Adult | 4 | 2021 | 11712 | 0.120 |
Why?
|
Sulfur Compounds | 1 | 2013 | 7 | 0.120 |
Why?
|
X Chromosome | 2 | 2006 | 30 | 0.120 |
Why?
|
Imines | 1 | 2013 | 10 | 0.120 |
Why?
|
Binding Sites, Antibody | 2 | 2010 | 20 | 0.120 |
Why?
|
Blood Volume Determination | 1 | 2013 | 1 | 0.120 |
Why?
|
Blood Volume | 1 | 2013 | 5 | 0.120 |
Why?
|
Magnetic Resonance Angiography | 1 | 2013 | 11 | 0.120 |
Why?
|
Kidney Function Tests | 1 | 2013 | 29 | 0.120 |
Why?
|
Renal Circulation | 1 | 2013 | 21 | 0.120 |
Why?
|
Recombinant Proteins | 4 | 2008 | 515 | 0.110 |
Why?
|
RNA, Messenger | 4 | 2012 | 1207 | 0.110 |
Why?
|
Haplorhini | 1 | 2013 | 22 | 0.110 |
Why?
|
Protein Interaction Domains and Motifs | 1 | 2013 | 42 | 0.110 |
Why?
|
Antibodies, Antineutrophil Cytoplasmic | 1 | 2012 | 1 | 0.110 |
Why?
|
Microscopic Polyangiitis | 1 | 2012 | 1 | 0.110 |
Why?
|
Biopsy | 2 | 2015 | 164 | 0.110 |
Why?
|
Paraquat | 1 | 2012 | 21 | 0.110 |
Why?
|
Mice, Congenic | 1 | 2012 | 2 | 0.110 |
Why?
|
Immunity, Cellular | 1 | 2012 | 70 | 0.100 |
Why?
|
Epitopes, T-Lymphocyte | 1 | 2012 | 57 | 0.100 |
Why?
|
Pulmonary Alveoli | 1 | 2012 | 27 | 0.100 |
Why?
|
Receptors, IgG | 1 | 2012 | 50 | 0.100 |
Why?
|
Ascorbic Acid | 1 | 2012 | 66 | 0.100 |
Why?
|
Middle Aged | 3 | 2021 | 10129 | 0.100 |
Why?
|
Extracellular Matrix | 2 | 2013 | 115 | 0.100 |
Why?
|
Immunization | 1 | 2012 | 92 | 0.100 |
Why?
|
Binding Sites | 2 | 2008 | 651 | 0.100 |
Why?
|
Precipitin Tests | 2 | 2002 | 52 | 0.100 |
Why?
|
Kidney Diseases | 1 | 2013 | 167 | 0.100 |
Why?
|
Immunohistochemistry | 2 | 2005 | 893 | 0.100 |
Why?
|
Histidine | 2 | 2004 | 42 | 0.100 |
Why?
|
Surface Properties | 2 | 2004 | 130 | 0.100 |
Why?
|
Chromosomes, Human, X | 1 | 2010 | 22 | 0.090 |
Why?
|
Peptide Fragments | 3 | 2004 | 308 | 0.090 |
Why?
|
Mesangial Cells | 2 | 2009 | 9 | 0.090 |
Why?
|
Cross Reactions | 1 | 2010 | 83 | 0.090 |
Why?
|
Mutation, Missense | 1 | 2010 | 83 | 0.090 |
Why?
|
Models, Biological | 3 | 2008 | 677 | 0.090 |
Why?
|
T-Lymphocytes, Helper-Inducer | 1 | 2009 | 42 | 0.090 |
Why?
|
Blotting, Western | 2 | 2002 | 859 | 0.090 |
Why?
|
Th1 Cells | 1 | 2009 | 92 | 0.090 |
Why?
|
T-Lymphocyte Subsets | 1 | 2009 | 88 | 0.080 |
Why?
|
MicroRNAs | 1 | 2014 | 426 | 0.080 |
Why?
|
Hydra | 1 | 2008 | 4 | 0.080 |
Why?
|
Binding, Competitive | 2 | 2000 | 111 | 0.080 |
Why?
|
Stem Cell Transplantation | 1 | 2008 | 31 | 0.080 |
Why?
|
Betamethasone | 1 | 2008 | 2 | 0.080 |
Why?
|
Cerebral Ventricles | 1 | 2008 | 23 | 0.080 |
Why?
|
Heparan Sulfate Proteoglycans | 1 | 2008 | 12 | 0.080 |
Why?
|
Signal Transduction | 1 | 2016 | 1908 | 0.070 |
Why?
|
Models, Immunological | 1 | 2007 | 21 | 0.070 |
Why?
|
Neuroglia | 1 | 2008 | 124 | 0.070 |
Why?
|
Transplantation Chimera | 1 | 2007 | 7 | 0.070 |
Why?
|
Heparin | 2 | 1998 | 35 | 0.070 |
Why?
|
Fibroblast Growth Factors | 1 | 2007 | 33 | 0.070 |
Why?
|
Neuromuscular Junction | 1 | 2007 | 33 | 0.070 |
Why?
|
Motor Neurons | 1 | 2007 | 83 | 0.070 |
Why?
|
Integrin alpha1 | 1 | 2006 | 2 | 0.070 |
Why?
|
Integrin alpha1beta1 | 1 | 2006 | 2 | 0.070 |
Why?
|
Survival | 1 | 2006 | 8 | 0.070 |
Why?
|
Integrin alpha3beta1 | 1 | 2006 | 1 | 0.070 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2007 | 80 | 0.070 |
Why?
|
Integrin alphaVbeta3 | 1 | 2006 | 12 | 0.070 |
Why?
|
Anti-Inflammatory Agents | 1 | 2008 | 149 | 0.070 |
Why?
|
Cerebral Cortex | 1 | 2008 | 290 | 0.070 |
Why?
|
Transplantation Immunology | 1 | 2005 | 5 | 0.070 |
Why?
|
Fatal Outcome | 1 | 2005 | 40 | 0.070 |
Why?
|
Biopsy, Needle | 1 | 2005 | 60 | 0.070 |
Why?
|
Diabetic Nephropathies | 1 | 2006 | 61 | 0.070 |
Why?
|
Graft Rejection | 1 | 2005 | 38 | 0.070 |
Why?
|
Protein Denaturation | 1 | 2005 | 43 | 0.070 |
Why?
|
Hemostatics | 1 | 2005 | 8 | 0.070 |
Why?
|
Phenotype | 2 | 2005 | 689 | 0.060 |
Why?
|
Blood Coagulation | 1 | 2005 | 23 | 0.060 |
Why?
|
Macromolecular Substances | 1 | 2005 | 96 | 0.060 |
Why?
|
Immunoassay | 1 | 2005 | 61 | 0.060 |
Why?
|
Recurrence | 1 | 2005 | 131 | 0.060 |
Why?
|
Solutions | 1 | 2004 | 62 | 0.060 |
Why?
|
Adsorption | 1 | 2004 | 68 | 0.060 |
Why?
|
Proline | 1 | 2004 | 43 | 0.060 |
Why?
|
Catalysis | 1 | 2004 | 179 | 0.060 |
Why?
|
Mutation | 2 | 2016 | 1095 | 0.060 |
Why?
|
Transfection | 1 | 2005 | 523 | 0.060 |
Why?
|
Chimera | 1 | 2003 | 15 | 0.060 |
Why?
|
Ligands | 1 | 2005 | 349 | 0.060 |
Why?
|
Neoplasm Metastasis | 1 | 2005 | 219 | 0.060 |
Why?
|
Rats, Inbred WKY | 1 | 2023 | 23 | 0.060 |
Why?
|
Gene Expression | 1 | 2007 | 674 | 0.060 |
Why?
|
Molecular Biology | 1 | 2003 | 46 | 0.060 |
Why?
|
Risk Assessment | 1 | 2005 | 753 | 0.050 |
Why?
|
Cells, Cultured | 4 | 2007 | 1518 | 0.050 |
Why?
|
Fluorescent Antibody Technique | 2 | 2015 | 189 | 0.050 |
Why?
|
Crystallography, X-Ray | 1 | 2002 | 265 | 0.050 |
Why?
|
Fluorescent Antibody Technique, Indirect | 1 | 2001 | 35 | 0.050 |
Why?
|
Urinary Bladder | 1 | 2001 | 29 | 0.050 |
Why?
|
Cross-Linking Reagents | 2 | 2013 | 51 | 0.050 |
Why?
|
Electrophoresis, Gel, Two-Dimensional | 1 | 2001 | 78 | 0.050 |
Why?
|
Microscopy, Electron | 1 | 2001 | 209 | 0.050 |
Why?
|
Electrophoresis, Polyacrylamide Gel | 1 | 2001 | 201 | 0.050 |
Why?
|
Immunodominant Epitopes | 1 | 2000 | 27 | 0.050 |
Why?
|
Immune Sera | 2 | 1999 | 59 | 0.050 |
Why?
|
Up-Regulation | 2 | 2014 | 513 | 0.050 |
Why?
|
Protein Subunits | 2 | 2015 | 87 | 0.050 |
Why?
|
Aorta | 1 | 2001 | 167 | 0.050 |
Why?
|
Antibody Affinity | 1 | 2000 | 25 | 0.040 |
Why?
|
Promoter Regions, Genetic | 1 | 2002 | 515 | 0.040 |
Why?
|
Chromatography, Affinity | 1 | 2000 | 67 | 0.040 |
Why?
|
Extracellular Matrix Proteins | 2 | 2013 | 67 | 0.040 |
Why?
|
Dermatan Sulfate | 1 | 1998 | 1 | 0.040 |
Why?
|
Chondroitin Sulfates | 1 | 1998 | 9 | 0.040 |
Why?
|
Reactive Oxygen Species | 2 | 2014 | 461 | 0.040 |
Why?
|
Base Sequence | 2 | 1999 | 997 | 0.040 |
Why?
|
Metals | 1 | 1998 | 98 | 0.040 |
Why?
|
Thermodynamics | 1 | 1998 | 216 | 0.040 |
Why?
|
Chlorides | 1 | 1997 | 56 | 0.040 |
Why?
|
Molecular Weight | 1 | 1997 | 167 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2000 | 1039 | 0.040 |
Why?
|
Biosensing Techniques | 1 | 1998 | 86 | 0.040 |
Why?
|
Receptors, Complement 3b | 1 | 2016 | 4 | 0.040 |
Why?
|
Isoelectric Point | 1 | 1996 | 9 | 0.030 |
Why?
|
Kinetics | 1 | 1998 | 708 | 0.030 |
Why?
|
Cell Adhesion | 2 | 2008 | 212 | 0.030 |
Why?
|
Plasma Exchange | 1 | 2015 | 5 | 0.030 |
Why?
|
Rats | 1 | 2023 | 3483 | 0.030 |
Why?
|
DNA, Complementary | 1 | 1996 | 191 | 0.030 |
Why?
|
Protein Structure, Secondary | 1 | 1996 | 183 | 0.030 |
Why?
|
Disulfides | 1 | 1996 | 77 | 0.030 |
Why?
|
Cloning, Molecular | 1 | 1996 | 325 | 0.030 |
Why?
|
Glucocorticoids | 1 | 2015 | 86 | 0.030 |
Why?
|
Mice, Inbred BALB C | 2 | 2007 | 661 | 0.030 |
Why?
|
Metabolic Networks and Pathways | 1 | 2014 | 67 | 0.030 |
Why?
|
Predictive Value of Tests | 1 | 2015 | 400 | 0.030 |
Why?
|
Peroxidases | 1 | 2013 | 15 | 0.030 |
Why?
|
Fibrosis | 1 | 2014 | 159 | 0.030 |
Why?
|
Blood Flow Velocity | 1 | 2013 | 61 | 0.030 |
Why?
|
DNA Primers | 2 | 2008 | 286 | 0.030 |
Why?
|
Image Enhancement | 1 | 2013 | 40 | 0.030 |
Why?
|
Oxidative Stress | 2 | 2012 | 938 | 0.030 |
Why?
|
Heme | 1 | 2013 | 70 | 0.030 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2013 | 61 | 0.030 |
Why?
|
Sequence Analysis, RNA | 1 | 2013 | 106 | 0.030 |
Why?
|
Neutrophil Activation | 1 | 2012 | 4 | 0.030 |
Why?
|
Imaging, Three-Dimensional | 1 | 2013 | 84 | 0.030 |
Why?
|
Founder Effect | 1 | 2012 | 9 | 0.030 |
Why?
|
Zebrafish | 1 | 2013 | 128 | 0.030 |
Why?
|
F2-Isoprostanes | 1 | 2012 | 20 | 0.030 |
Why?
|
Mass Spectrometry | 1 | 2013 | 260 | 0.030 |
Why?
|
Albumins | 1 | 2012 | 26 | 0.030 |
Why?
|
Drosophila melanogaster | 1 | 2013 | 180 | 0.030 |
Why?
|
Organ Specificity | 1 | 2012 | 129 | 0.030 |
Why?
|
Sensitivity and Specificity | 1 | 2013 | 562 | 0.030 |
Why?
|
Models, Animal | 1 | 2012 | 134 | 0.030 |
Why?
|
Neutrophils | 1 | 2012 | 131 | 0.030 |
Why?
|
Peptides | 1 | 2013 | 320 | 0.020 |
Why?
|
Pedigree | 1 | 2010 | 79 | 0.020 |
Why?
|
Time Factors | 1 | 2015 | 1742 | 0.020 |
Why?
|
Heterozygote | 1 | 2010 | 93 | 0.020 |
Why?
|
Algorithms | 1 | 2013 | 465 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2013 | 935 | 0.020 |
Why?
|
Genes, RAG-1 | 1 | 2009 | 2 | 0.020 |
Why?
|
Adoptive Transfer | 1 | 2009 | 48 | 0.020 |
Why?
|
Ovalbumin | 1 | 2009 | 47 | 0.020 |
Why?
|
Adaptive Immunity | 1 | 2009 | 27 | 0.020 |
Why?
|
Interleukin-17 | 1 | 2009 | 53 | 0.020 |
Why?
|
Endothelium | 1 | 2009 | 31 | 0.020 |
Why?
|
Motor Activity | 1 | 2012 | 418 | 0.020 |
Why?
|
Liver | 1 | 2012 | 479 | 0.020 |
Why?
|
Chemokines | 1 | 2009 | 97 | 0.020 |
Why?
|
Renal Insufficiency | 1 | 2008 | 18 | 0.020 |
Why?
|
Cognition | 1 | 2012 | 398 | 0.020 |
Why?
|
Morphogenesis | 1 | 2008 | 50 | 0.020 |
Why?
|
Microscopy, Electron, Scanning | 1 | 2008 | 142 | 0.020 |
Why?
|
Conserved Sequence | 1 | 2008 | 119 | 0.020 |
Why?
|
Pericytes | 1 | 2008 | 22 | 0.020 |
Why?
|
In Situ Hybridization | 1 | 2008 | 129 | 0.020 |
Why?
|
Amino Acid Motifs | 1 | 2008 | 91 | 0.020 |
Why?
|
Fibronectins | 1 | 2008 | 66 | 0.020 |
Why?
|
Fetus | 1 | 2008 | 105 | 0.020 |
Why?
|
Gestational Age | 1 | 2008 | 190 | 0.020 |
Why?
|
Lac Operon | 1 | 2007 | 21 | 0.020 |
Why?
|
Chick Embryo | 1 | 2007 | 74 | 0.020 |
Why?
|
Myoblasts | 1 | 2007 | 27 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 1 | 2007 | 31 | 0.020 |
Why?
|
Mice, Inbred Strains | 1 | 2007 | 116 | 0.020 |
Why?
|
Organ Culture Techniques | 1 | 2007 | 103 | 0.020 |
Why?
|
Coculture Techniques | 1 | 2007 | 101 | 0.020 |
Why?
|
Presynaptic Terminals | 1 | 2007 | 53 | 0.020 |
Why?
|
Tissue Distribution | 1 | 2007 | 207 | 0.020 |
Why?
|
Analysis of Variance | 1 | 2008 | 550 | 0.020 |
Why?
|
Polymerase Chain Reaction | 1 | 2008 | 448 | 0.020 |
Why?
|
Integrins | 1 | 2006 | 51 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2007 | 161 | 0.020 |
Why?
|
Glomerular Filtration Rate | 1 | 2006 | 139 | 0.020 |
Why?
|
Cell Division | 1 | 2006 | 307 | 0.020 |
Why?
|
Neovascularization, Pathologic | 1 | 2006 | 127 | 0.020 |
Why?
|
Infant, Newborn | 1 | 2008 | 894 | 0.020 |
Why?
|
Diabetes Mellitus, Experimental | 1 | 2006 | 94 | 0.020 |
Why?
|
Anxiety | 1 | 2012 | 754 | 0.020 |
Why?
|
Glucose | 1 | 2006 | 230 | 0.020 |
Why?
|
Endothelium, Vascular | 1 | 2006 | 237 | 0.020 |
Why?
|
Aged, 80 and over | 1 | 2010 | 2379 | 0.010 |
Why?
|
Aging | 1 | 2008 | 664 | 0.010 |
Why?
|
Cell Movement | 1 | 2006 | 571 | 0.010 |
Why?
|
Child | 1 | 2010 | 3131 | 0.010 |
Why?
|
Capillary Permeability | 1 | 2000 | 30 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2006 | 807 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2006 | 1198 | 0.010 |
Why?
|
Mutagenesis, Site-Directed | 1 | 2000 | 188 | 0.010 |
Why?
|
Young Adult | 1 | 2010 | 4268 | 0.010 |
Why?
|
Protein Folding | 1 | 2000 | 127 | 0.010 |
Why?
|
Adolescent | 1 | 2010 | 5363 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2006 | 2231 | 0.010 |
Why?
|
Structure-Activity Relationship | 1 | 2000 | 409 | 0.010 |
Why?
|
Mutagenesis | 1 | 1999 | 89 | 0.010 |
Why?
|